CIK 0001374690
- Non-accelerated filer
- Smaller reporting company
Larimar Therapeutics, Inc.
Sign in to watch- Ticker
- LRMR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203857670
- Phone
- +1 844-511-9056
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Former names
- ZAFGEN, INC., ZAFGEN INC
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 64,545 shares at $6.25 ($403,187)
- 4 Open-market buy 10% owner bought 267,493 shares at an average $6.02 ($1,609,668)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 8,849 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 4,424 shares (grant or award)
- 4 Grant or award Director acquired 4,424 shares (grant or award)
- 4 Exercise or conversion Chief Executive Officer acquired 10,000 shares (option exercise)
- 4 Grant or award Director acquired 899 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4/A Open-market sale Chief Medical Officer sold 39,407 shares at $40.00 ($1,576,280)
- 4/A Open-market sale Chief Medical Officer sold 593 shares at $40.00 ($23,720)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 136,579 shares at an average $43.90 ($5,995,403)
- 4 Exercise or conversion Chief Executive Officer acquired 10,500 shares (option exercise)
Page 11 of 14 · 273 filings